Public Release: 

SVIN announces 'Stroke: Mission thrombectomy 2020'

An initiative to reduce disability from stroke worldwide

Society of Vascular and Interventional Neurology

IMAGE

IMAGE: This is the SVIN Logo. view more

Credit: Society of Vascular and Interventional Neurology

New York -- Nov.21, 2016 -- The Society of Vascular and Interventional Neurology (SVIN) announced the launch of Mission Thrombectomy 2020, an initiative to enhance global efforts to improve stroke care worldwide by increasing the rate of stroke thrombectomy for eligible patients from less than 100,000 procedures today to 202,000 annually by 2020 and thereby reducing global stroke disability. Stroke Thrombectomy, also known as Mechanical Thrombectomy, is the new highly effective standard of care that reverses paralysis from stroke in over 60% of patients if done by experts within 6 hours of stroke symptoms. The initiative was unveiled at the SVIN 9th Annual Meeting and 4th Annual Stroke Center Workshop, which took place from November 16-19, 2016 in Brooklyn, New York.

"In 2015, mechanical thrombectomy was definitively proven to be enormously beneficial in reversing stroke disability and become standard of care for stroke patients with blockage of one of the main brain arteries. This has revolutionized the treatment for such patients," said Dr. Dileep Yavagal, MD, Past President of SVIN, who is leading this effort. "SVIN has set an ambitious worldwide goal to treat every eligible stroke patients emergently with mechanical thrombectomy, but this can only be achieved if we maximize access to hospitals with mechanical thrombectomy capability of severe stroke with within six hours of their symptoms."

In order to maximize access to thrombectomy for the potential 1.7 million patients worldside with stroke due to a large artery blockage, SVIN aims to partner with several non-profit medical societies, governmental and industry collaborators worldwide to achieve their initiative by focusing on efforts to improve public awareness for stroke symptoms, supporting legislation to encourage rapid triage of stroke patients, establishing financial initiatives to improve access to care for countries without health insurance and encouraging the development of new technologies to improve stroke assessment and treatment. Currently less than 100,000 procedures are performed worldwide in 2016. One supporter announced at the meeting was Neural Analytics which demonstrated its Lucid™ System, a device designed to help improve rapid assessment of patients with brain blood flow disorders, at the meeting.

"Mission Thrombectomy 2020 advances the overall mission of SVIN of innovation to improve outcomes of the largest number of stroke patients all over the world" said Raul Nogueira, MD, President of SVIN. "This campaign will consolidate various efforts from multiple stakeholders with a clear patient metric to be achieved in 3 years."

"We are pleased to support SVIN on this important initiative to improve stroke treatment worldwide and help reduce the disability associated with this condition," said Robert Hamilton, Co-Founder & Chief Science Officer of Neural Analytics. "A critical component for effective stroke treatment is determining an accurate diagnosis as quickly as possible in settings inside and outside the hospital.

Globally each year, strokes affect about 16 million people and kill an estimated 5.7 million. The annual U.S. healthcare overall cost due to stroke is $104 billion. Stroke is a very time sensitive disease and requires intervention within six hours. Without appropriate diagnosis and treatment, a majority of surviving stroke patients suffer permanent disability. Despite the recent advances of mechanical thromectomy, which reduces disability and saves lives, less than 10 percent of eligible stroke patients are treated surgically due to the lack of a portable diagnostic device for early detection.1,2,3,4

###

About SVIN

SVIN is the premier society worldwide for medical professionals engaged in interventional neurology and stroke care. Our mission to promote excellence in the field of interventional treatment of neurovascular diseases by neurologists. The society represents the advancement of interventional neurology through education, research and advocacy with the ultimate goal of improving clinical care and outcomes of patients with stroke and cerebrovascular diseases.

The SVIN Annual Meeting is a premier academic venue with scientific presentations covering the full spectrum of cerebrovascular diseases and stroke. Participants have the opportunity to discuss embolectomy, aneurysms and AVMs, subarachnoid and intracranial hemorrhage, endovascular saves and innovative approaches, new device review, international perspectives, and other-related topics.

For further information about SVIN, please visit http://www.svin.org or find us on Facebook, Twitter or LinkedIn.

Contacts:

Dr. Dileep Yavagal, FSVIN
Board Director, Society of Vascular and Interventional Neurology
305-355-1103

Janel Fick
SIVN Executive Director
952-646-2023

Sources:

1. Ganesalingam, J. Cost Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke. Stroke. 2015 Sep;46(9):2591-8. doi: 10.1161/STROKEAHA.115.009396. Epub 2015 Aug 6.

2. Saver, J. et. Al. Stent Retriever Thrombectomy after Intraveneous t-PA vs. t_PA alone in stroke. N Engl J Med 2015; 372:2285-2295

3. Ovbiagele, B. et. Al Forecasting the Future of Stroke in the United States. Stroke. 2013. http://stroke.ahajournals.org/content/44/8/2361.abstract

4. Age Ageing (2009) 38 (1): 4-5.doi: 10.1093/ageing/afn282

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.